Transition Raises $11M in Private Placement
By Catherine Shaffer
Friday, August 2, 2013
Transition Therapeutics Inc. will receive an investment of up to $21 million from certain shareholders purchasing 2.5 million units of the company's stock at $4.19 per share. The financing will support the company through completion of three Phase II studies. Transition has compounds in development for Alzheimer's disease and bipolar disorder, and for Type II diabetes and obesity.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.